A Phase II Study of AP23573, an mTOR Inhibitor, in Female Adult Patients With Recurrent or Persistent Endometrial Cancer.
Phase of Trial: Phase II
Latest Information Update: 08 May 2014
At a glance
- Drugs Ridaforolimus (Primary)
- Indications Endometrial cancer
- Focus Therapeutic Use
- Sponsors ARIAD Pharmaceuticals; Merck & Co; Merck Sharp & Dohme
- 02 Jun 2010 Merck and Co added as trial sponsor, trial affiliate and Merck Sharp and Dohme added as trial affiliate, lead trial centres as reported by ClinicalTrials.gov.
- 24 Mar 2009 Additional lead trial investigator (Haluska F) identified as reported by ClinicalTrials.gov.
- 10 Sep 2008 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.